IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2668
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$200M
Jurgi Camblong
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Company was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$SOPH SOPHiA GENETICS SA | 46 | 44 | 10 | 57 | - | - | -259.1% | -160.9% | 67.4% | -102.1% | -95.9% | 4.5% | 0.0% | 31.0x | $200M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
SOPHiA GENETICS SA (SOPH) receives a "Reduce" rating with a composite score of 45.8/100. It ranks #2668 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Jurgi Camblong
Chief Executive Officer
Labor Force
520
44
65
46
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for SOPH
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Conservative, efficient capex — capital discipline signals management quality
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SOPH.
View All RatingsImproving capital utilization rates confirmed
ROE proxy -259.1% (sector -2.5%)
GM 67% vs sector 43%, OM -102% vs sector 1%
Capital turnover N/A, R&D intensity 52.7%
Rev growth 4%, 4yr history
Interest coverage -34.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
SOPHiA GENETICS SA receives a Reduce rating from our analysis, with a composite score of 45.8/100 and 2 out of 5 stars, ranking #2668 out of 7,333 stocks. SOPH's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
SOPH's quality score of 44/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -259.1% (sector avg: -2.5%), gross margins of 67.4% (sector avg: 42.5%), net margins of -95.9% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
SOPH registers a value score of just 10/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.34x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
SOPH shows a solid investment score of 65/100, reflecting measured but productive capital allocation. Key growth metrics include revenue growth of 4.5% vs. a sector average of 5.9% and a return on assets of -160.9% (sector: -0.1%). This suggests the company is investing at an appropriate level to sustain growth without overextending its balance sheet.
SOPH demonstrates moderate momentum with a score of 57/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 4.5% year-over-year, while a beta of 1.27 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 46/100, SOPH exhibits average financial resilience. Key stability metrics include a beta of 1.27 and a debt-to-equity ratio of 31.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 52/100 for SOPH suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.27), elevated leverage (D/E: 31.00x), micro-cap liquidity risk. With a $200M market cap (micro-cap), SOPHiA GENETICS SA may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
SOPHiA GENETICS SA is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2668 of 7,333 overall (64th percentile). Key comparisons include ROE of -259.1% trailing the -2.5% sector median and operating margins of -102.1% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SOPH currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (10) would have the largest impact on the composite score.
ROE 10346% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 59% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 8018% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate SOPHiA GENETICS SA (SOPH) as a Reduce with a composite score of 45.8/100 at a current price of $4.55. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in investment (65th percentile) and momentum (57th percentile), which together account for the majority of the composite score. Offsetting weakness in value (10th percentile) and quality (44th percentile) tempers our overall conviction. We assign a Narrow Moat rating (45/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
SOPHiA GENETICS SA holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 45.8/100 places it at rank #2668 in our full 7,333-stock universe. At $200M in market capitalization, SOPHiA GENETICS SA is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 4%, though momentum at the 57th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 67% (+24.9pp vs sector) narrow to operating margins of -102% (-103.4pp vs sector) and net margins of -95.9%, yielding a gross-to-net conversion rate of -142%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $4.55, SOPHiA GENETICS SA is trading at a premium to fundamental value. Our value factor score of 10/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 3.3x, P/S of 1.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 67% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
The Reduce rating (composite 45.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -95.9% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to SOPHiA GENETICS SA. Key risk factors include current negative profitability (net margin -95.9%). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -95.9%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 46th percentile and quality factor at the 44th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 67% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate SOPHiA GENETICS SA's capital allocation as Poor. Key concerns include low returns on equity (-259.1%), negative profitability, weak asset returns (ROA -160.9%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — SOPHiA GENETICS SA significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, SOPHiA GENETICS SA receives a Reduce rating with a composite score of 45.8/100 (rank #2668 of 7,333). Our quantitative framework assigns a Narrow Moat (45/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 44/100.
Our analysis does not support a constructive view on SOPHiA GENETICS SA at this time. The combination of the current quantitative profile, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign SOPHiA GENETICS SA a Narrow Moat rating with a composite moat score of 45/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that SOPHiA GENETICS SA can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being reinvestment efficiency at 14/20.
The strongest moat sources are reinvestment efficiency (14/20) and margin superiority (12.1/20). Capital turnover N/A, R&D intensity 52.7%. GM 67% vs sector 43%, OM -102% vs sector 1%. These pillars form the core of SOPHiA GENETICS SA's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (3.9/20) and financial resilience (5.9/20). ROE proxy -259.1% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect SOPHiA GENETICS SA's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 67% providing a solid profitability foundation. The margin cascade from 67% gross to -102% operating to -95.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 44th percentile.
The margin profile shows gross margins of 67%, operating margins of -102%, net margins of -95.9%. Return metrics include ROE of -259.1% and ROA of -160.9%. Relative to the Manufacturing sector, gross margins are 24.9 percentage points above the sector median of 43%, and ROE of -259.1% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 31%, revenue growth of 4%. The sector median D/E is 0%, putting SOPHiA GENETICS SA at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.
Key Insights The considerable ownership by individual investors in SOPHiA GENETICS indicates that they collectively...
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from Benzinga Pro. United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer. United Natural Foods shares dipped 15.2% to $12.61 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line. Aptorum Group Limited (NASDAQ: APM) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business. NKGen Biotech, Inc. (NASDAQ: NKGN) gained 46.5% to $1.35. TRxADE HEALTH, Inc. (NASDAQ: MEDS) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share. Airship AI Holdings, Inc. (NASDAQ: AISP) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform. Enviva Inc. (NYSE: EVA) rose 33% to $0.9854 after gaining 42% on Tuesday. American Public Education, Inc. (NASDAQ: APEI) gained 31.8% to $14.99 following upbeat quarterly results. Dada Nexus Limited (NASDAQ: DADA) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements. Cemtrex, Inc. (NASDAQ: CETX) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature. Wave Life Sciences Ltd. (NYSE: WVE) gained 28.5% to $6.16 following upbeat quarterly results. Vincerx Pharma, Inc. (NASDAQ: VINC) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024. XORTX Therapeutics Inc. (NASDAQ: XRTX) rose 24.2% to $5.85. CareMax, Inc. (NASDAQ: CMAX) gained 23.8% to ...